[1] BOZIC M，CAUS M，RODRIGUES-DIEZ R R，et al.Protective role of renal proximal tubular alpha-synuclein in the pathogenesis of kidney fibrosis[J].Nat Commun，2020，11(1):1943-1959.
[2] 陈娟，唐文庄，张瑞城，等.糖尿病肾病患者外周血微小RNA-30c表达与肾间质纤维化的关系[J].现代医学，2020，48(7)：813-816.
[3] PENG H，WANG Q，LOU T，et al.Myokine mediated muscle-kidney crosstalk suppresses metabolic reprogramming and fibrosis in damaged kidneys[J].Nat Commun，2017，8(1):1493-1508.
[4] DHILLON P，PARK J，HURTADO D P C，et al.The nuclear receptor ESRRA protects from kidney disease by coupling metabolism and differentiation[J].Cell Metab，2021,33(2):379-394.
[5] SOUZA A C，BOCHAROV A V，BARANOVA I N，et al.Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation[J].Kidney Int，2016，89(4):809-822.
[6] FERRO C J，MARK P B，KANBAY M，et al.Lipid management in patients with chronic kidney disease[J].Nat Rev Nephrol,2018,14(12):727-749.
[7] KANG H M，AHN S H，CHOI P，et al.Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development[J].Nat Med，2015，21(1):37-46.
[8] ALLISON S J.Sting activation by cytoplasmic mtDNA triggers renal inflammation and fibrosis[J].Nat Rev Nephrol,2019,15(11):661-662.
[9] MIGUEL V，TITUANA J，HERRERO J I，et al.Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis[J].J Clin Invest,2021,131(5):140-191.
[10] YUAN Q，LÜ Y，DING H，et al.CPT1α maintains phenotype of tubules via mitochondrial respiration during kidney injury and repair[J].Cell Death Dis,2021,12(8):792-804.
[11] GAO J，GU Z.The role of peroxisome proliferator-activated receptors in kidney diseases[J].Front Pharmacol，2022，13(5):832-842.
[12] 张锐，曾嘉，邓志军，等.PGC1α通过调控肾组织脂肪酸代谢在肾纤维化中发挥枢纽作用[J].中南大学学报(医学版)，2022，47(6)：786-793.
[13] PAWLAK M，LEFEBVRE P，STAELS B.Molecular mechanism of PPARα action and its impact on lipid metabolism，inflammation and fibrosis in non-alcoholic fatty liver disease[J].J Hepatol，2015，62(3):720-733.
[14] TRAN M T，ZSENGELLER Z K，BERG A H，et al.PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection[J].Nature，2016，531(7595):528-532.
[15] ZHANG L，LIU J，ZHOU F，et al.PGC-1α ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism[J].Mol Med Rep，2018，17(3):4490-4498.
[16] DUCASE G M，MITROFANOVA A，MALLELA S K，et al.ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes[J].J Clin Invest，2019，129(8):3387-3400.
[17] LI J，YANG Y，LI Q，et al.STAT6 contributes to renal fibrosis by modulating PPARα-mediated tubular fatty acid oxidation[J].Cell Death Dis，2022，13(1):66-77.
[18] CHUNG K W，HA S，KIM S M，et al.PPARα/β activation alleviates age-associated renal fibrosis in sprague dawley rats[J].J Gerontol A Biol Sci Med Sci，2020，75(3):452-458.
[19] PODRINI C，CASSINA L，BOLETTA A.Metabolic reprogramming and the role of mitochondria in polycystic kidney disease[J].Cell Signal，2020，67(2):109-140.
[20] PODRINI C，ROWE I，PAGLIARINI R，et al.Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways[J].Commun Biol，2018，1(5):194-208.
[21] LAKHIA R，YHESKEL M，FLATEN A，et al.PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice[J].Am J Physiol Renal Physiol，2018，314(1):122-131.
[22] HOUTEN S M，VIOLANTE S，VENTURA F V，et al.The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic disorders[J].Annu Rev Physiol，2016，78(5):23-44.
[23] KHAN S，GAIVIN R，ABRAMOVICH C，et al.Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression[J].JCI Insight,2020，5(15):136-177.
[24] CHEN Y，YAN Q，LÜ M，et al.Involvement of FATP2-mediated tubular lipid metabolic reprogramming in renal fibrogenesis[J].Cell Death Dis,2020，11(11):994-1009.
[25] HARDIE D G，SCHAFFER B E，BRUNET A.AMPK:an energy-sensing pathway with multiple inputs and outputs[J].Trends Cell Biol，2016，26(3):190-201.
[26] SAMOVSKI D，SUN J，PIETKA T，et al.Regulation of AMPK activation by CD36 links fatty acid uptake to β-oxidation[J].Diabetes，2015，64(2):353-359.
[27] HUA W，HUANG H Z，TAN L T，et al.CD36 mediated fatty acid-induced podocyte apoptosis via oxidative stress[J].PLoS One，2015，10(5):1371-1385.
[28] TANAKA M，TAKAHASHI S，HIGASHIURA Y，et al.Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals[J].Diabetes Investig，2021，10(11):137-147.
[29] FURUHASHI M.Fatty acid-binding protein 4 in cardiovascular and metabolic diseases[J].Atheroscler Thromb,2019，26(3):216-232.
[30] QIAO Y，LIU L，YIN L，et al.FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism[J].Cell Death Dis，2019，10(6):382-394.
[31] ZHOU S，WANG X，SHI J，et al.Serum fatty acid binding protein 4 levels are associated with abdominal aortic calcification in peritoneal dialysis patients[J].Ren Fail，2021，43(1):1539-1548.
[32] FENG Y，GUO F，XIA Z，et al.Inhibition of fatty acid-binding protein 4 attenuated kidney fibrosis by mediating macrophage-to-myofibroblast transition[J].Front Immunol，2020，11(2):566-578.
[33] DOROTEA D，KOYA D，HA H.Recent insights into SREBP as a direct mediator of kidney fibrosis via lipid-independent pathways[J].Front Pharmacol,2020,11(4):265-281.
[34] LI L，TAO S，GUO F，et al.Genetic and pharmacological inhibition of fatty acid-binding protein 4 alleviated inflammation and early fibrosis after toxin induced kidney injury[J].Int Immunopharmacol，2021，96(5):760-770.
[35] MENG X M，NIKOLIC-PATERSON D J，LAN H Y.TGF-β:the master regulator of fibrosis[J].Nat Rev Nephrol,2016,12(6):325-338.
[36] SONG M K，LEE J H，RYOO I G,et al.Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation[J].Free Radic Biol Med，2019，138(8):33-42.
[37] ZHAO X，KWAN J Y Y，YIP K，et al.Targeting metabolic dysregulation for fibrosis therapy[J].Nat Rev Drug Discov,2020,19(1):57-75.
[38] ZHAO X，PSARIANOS P，GHORAIE L S，et al.Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis[J].Nat Metab，2019，1(1):147-157.
[39] LAKSHMI S P，REDDY A T，REDDY R C.Transforming growth factor β suppresses peroxisome proliferator-activated receptor γ expression via both SMAD binding and novel TGF-β inhibitory elements[J].Biochem J，2017，474(9):1531-1546.
[40] CHEN Y，DAI Y，SONG K，et al.Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism[J].Cell Death Dis,2021，12(6):572-586.
[41] MUSTAFA M，WANG T N，CHEN X，et al.SREBP inhibition ameliorates renal injury after unilateral ureteral obstruction[J].Am J Physiol Renal Physiol,2016,311(3):614-625.
[42] SRIVASTAVA S P，LI J，KITADA M，et al.SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis[J].Cell Death Dis,2018，9(10):997-1011.
[43] HUA W，TENDIJKE P，KOSTIDIS S，et al.TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer[J].Cell Mol Life Sci,2020，77(11):2103-2123.
[44] ESCASANY E，LANZON B，GARCIA-CARRASCO A，et al.Transforming growth factor β3 deficiency promotes defective lipid metabolism and fibrosis in murine kidney[J].Dis Model Mech,2021,14(9):48-107.
[45] WANNER C，TONELLI M.Kidney disease:improving global outcomes lipid guideline development work group members.KDIGO clinical practice guideline for lipid management in CKD:summary of recommendation statements and clinical approach to the patient[J].Kidney Int,2014，85(6):1303-1309.
[46] AOMURA D，HARADA M，YAMADA Y，et al.Pemafibrate protects against fatty acid-induced nephropathy by maintaining renal fatty acid metabolism[J].Metabolites，2021，11(6):372-385.
[47] HUANG C C，CHOU C A，CHEN W Y，et al.Empagliflozin ameliorates free fatty acid induced-lipotoxicity in renal proximal tubular cells via the PPARγ/CD36 pathway in obese mice[J].Int J Mol Sci,2021，22(22):12408-12423. |
